Go Deep
Zenas BioPharma, Inc.
Zenas BioPharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,443 | -2.6 | 6.64 | 1.21 | 2,396.08 |
| Oct 2026 | 17,516 | -2.6 | 6.56 | 1.21 | 2,360.39 |
| Oct 2026 | 17,385 | -2.7 | 6.70 | 1.21 | 2,412.01 |
| Oct 2026 | 17,521 | -2.6 | 6.55 | 1.21 | 2,352.72 |
| Oct 2026 | 17,065 | -2.8 | 7.04 | 1.21 | 2,532.55 |
| Oct 2026 | 16,706 | -2.9 | 7.43 | 1.21 | 2,671.93 |
| Oct 2026 | 16,730 | -2.9 | 7.41 | 1.21 | 2,655.87 |
| Oct 2026 | 16,694 | -2.9 | 7.45 | 1.21 | 2,664.65 |
Zenas BioPharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,000,000.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -111,456,000.0 | -80,987,000.0 | -240,442,000.0 | -51,499,000.0 |
| EPS | -1.8 | -1.5 | -4.5 | -1.2 |
Zenas BioPharma, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 10,000,000.0 | 5,000,000.0 | 50,000,000.0 | 0.0 |
| Net Profit | -377,737,000.0 | -156,988,000.0 | -37,124,000.0 | -119,282,000.0 |
| EPS | -8.4 | -11.9 | -2.1 | -9.3 |
Zenas BioPharma, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 383,640,000.0 | 369,968,000.0 | 68,180,000.0 | 74,579,000.0 |
| Total Liabilities | 141,496,000.0 | 57,510,000.0 | 293,901,000.0 | 266,865,000.0 |
| Total Equity | 242,144,000.0 | 312,458,000.0 | -225,721,000.0 | -192,286,000.0 |
Owes vs Owns
Zenas BioPharma, Inc. owed $0.65 for every $1 it owned in Jun 2026, down from $3.58 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.65× | 0.37× | 0.16× | 4.31× | 3.58× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Zenas BioPharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 89.5%Long-term investments 4.5%Other assets 5.7%
How it's funded — Dec 2025
Payables 1.9%Other liabilities 34.7%Shareholders' equity 63.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 343.2 | 350.8 | 56.9 | 67.2 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.4 | 1.2 | 1.0 | 1.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 17.3 | 0.0 | 0.0 | 0.0 |
| Other assets | 21.8 | 18.0 | 10.3 | 5.6 |
| Liabilities & equity | ||||
| Short-term debt | 1.1 | 0.8 | 0.6 | 0.7 |
| Long-term debt | 0.2 | 0.2 | 20.3 | 0.8 |
| Payables | 7.1 | 17.1 | 5.4 | 5.8 |
| Other liabilities | 133.1 | 39.4 | 267.6 | 259.5 |
| Shareholders' equity | 242.1 | 312.5 | -225.7 | -192.3 |
| Net tangible assets | 242.1 | 312.5 | -225.7 | -192.3 |
Zenas BioPharma, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -172,333,000.0 | -119,674,000.0 | -30,529,000.0 | -65,652,000.0 |
| Investing Activities | -251,886,000.0 | -30,552,000.0 | -17,000.0 | -2,198,000.0 |
| Financing Activities | 215,280,000.0 | 412,958,000.0 | 20,116,000.0 | 59,391,000.0 |